Unveiling Multiple Endocrine Neoplasia Type 1 (MEN-1) in a Young Pakistani Male with Recurrent Hypoglycemia: A Diagnostic Odyssey in a Resource-Limited Setting

Year 2025, Volume: 7 Issue: 4, 141 - 146, 29.10.2025

Zoha Rehman , Dr. Noshaba Razaq Dr. Wajahat Sultan Baig , Amara Anees Zunaira Abbas Zavata Afnan Hamna Khalid Hamna Nasir

https://izlik.org/JA66WM82RN

Abstract

This case report describes a 32-year-old Pakistani male who was initially admitted to a tertiary care hospital with Typhoid fever, but later developed recurrent life-threatening hypoglycemia. Extensive investigations revealed elevated insulin and C-peptide levels, a pituitary microadenoma, and a somatostatin-avid gastric lesion, leading to the diagnosis of Multiple Endocrine Neoplasia type 1 (MEN-1). Management included dextrose infusions, somatostatin-analogue therapy, and supportive care. The case highlights the diagnostic challenges of MEN-1 in atypical presentations and resource-limited settings, underscoring the need for a multidisciplinary approach to treatment and psychosocial support.

Keywords

MEN-1 Syndrome , Insulinoma , Pituitary Adenoma , Hypoglycemia

Ethical Statement

THIS RESEARCH HAS BEEN CONDUCTED WITH PROPER SIGNED INFORMED CONSENT AND CONSIDERING ALL ETHICAL ASPECTS OF A RESEARCH WORK.

Supporting Institution

WAH MEDICAL COLLEGE , POF HOSPITAL , WAHCANTT

Project Number

not applicable

Thanks

THANKS .

References

• Panzuto F, Barbi S, Trama A, Fazio N. The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management. Cancer Treat Rev. 2025 Sept;139:102998.
• Brandi ML, Pieterman CR, Lines KE, Stevenson M, Marini F, Cuny T, et al. Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice. Lancet Diabetes Endocrinol. 2025 Sep;13(9):665–82. doi:10.1016/S2213-8587(25)00119-6
• Bruno Vergès, Françoise Boureille, Pierre Goudet, Arnaud Murat, Albert Beckers, Geneviève Sassolas, Patrick Cougard, Béatrice Chambe, Corinne Montvernay, Alain Calender, Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study, The Journal of Clinical Endocrinology & Metabolism, Volume 87, Issue 2, 1 February 2002, Pages 457–465, https://doi.org/10.1210/jcem.87.2.8145
• Thakker R. V. (2010). Multiple endocrine neoplasia type 1 (MEN1). Best practice & research. Clinical endocrinology & metabolism, 24(3), 355–370. https://doi.or
• Biermasz N. R. (2019). The burden of disease for pituitary patients. Best practice & research. Clinical endocrinology & metabolism, 33(2), 101309. https://doi.org/10.1016/j.beem.2019.101309.
• Hofland J, Refardt JC, Feelders RA, Christ E, De Herder WW. Approach to the Patient: Insulinoma. J Clin Endocrinol Metab. 2024 Mar 15;109(4):1109–18.
• Zhang WD, Liu DR, Wang P, Zhao JG, Wang ZF, Chen L. Clinical treatment of gastrinoma: A case report and review of the literature. Oncol Lett. 2016 May;11(5):3433–7.
• Cheng S, Xu S, Guo J, He Q, Li A, Huang L, et al. Risk factors of central venous catheter-related bloodstream infection for continuous renal replacement therapy in kidney intensive care unit patients. Blood Purif. 2019;48(2):175–82. doi:10.1159/000495024.
• Băicoianu-Nițescu LC, Gheorghe AM, Carsote M, Dumitrascu MC, Sandru F. Approach of Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome–Related Skin Tumors. Diagnostics. 2022 Nov 12;12(11):2768.
• Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia. Ther Adv Endocrinol Metab. 2020 Jan;11:2042018820965068.